336 - Centrally administered prostaglandin E2 suppresses the rat micturition reflex via brain EP1 and EP2 receptors

Prostaglandin E2 (PGE2) is reported to facilitate the micturition reflex at levels of the lower urinary tract (LUT) and the spinal cord [1]. However, roles of brain PGE2 in regulation of the reflex are unclear. In previous reports, intracerebroventricularly (icv) administered PGE2 elevated plasma no...

Full description

Saved in:
Bibliographic Details
Published inContinence (Amsterdam) Vol. 15; p. 102260
Main Authors Shimizu, T, Shimizu, N, Tsubouchi, S, Togo, M, Higashi, Y, Saito, M
Format Journal Article
LanguageEnglish
Published Elsevier B.V 2025
Subjects
Online AccessGet full text
ISSN2772-9737
2772-9737
DOI10.1016/j.cont.2025.102260

Cover

Abstract Prostaglandin E2 (PGE2) is reported to facilitate the micturition reflex at levels of the lower urinary tract (LUT) and the spinal cord [1]. However, roles of brain PGE2 in regulation of the reflex are unclear. In previous reports, intracerebroventricularly (icv) administered PGE2 elevated plasma noradrenaline [2], which can affect the micturition reflex. In this study, therefore, we investigated effects of icv administered PGE2 on the rat micturition reflex. In urethane-anesthetized (0.8 g/kg, ip) male Wistar rats (300-450 g), a catheter was inserted into the bladder to perform cystometry. Two hours after the surgery, cystometry (saline instillation at 12 ml/h) was started to evaluate intercontraction interval (ICI), threshold pressure for inducing micturition (TP) and maximal voiding pressure (MVP). One hour after the start, PGE2 (0.1, 0.3 or 1 nmol/rat) or vehicle was icv administered. Evaluations of these parameters were continued 2 h after the administration. When using each antagonist for E-prostanoid receptor subtypes (EP1-EP4), SC51322 (EP1 antagonist), PF04418948 (EP2 antagonist), L-798106 (EP3 antagonist) or L-161982 (EP4 antagonist) was icv pretreated at 100 nmol/rat 30 min before PGE2 administration (1 nmol/rat, icv). In some rats, 6-hydroxydopamine (6-OHDA), which induces chemical sympathectomy, was administered (100 mg/kg, ip) once a day for 3 days. At one day after the third administration, PGE2 was administered (1 nmol/rat, icv) and urodynamic parameters were evaluated in addition to measuring mean blood pressure (MBP) through an arterial catheter. PGE2 dose-dependently increased ICI and TP (Fig. 1) without changing MVP (data not shown). In 6-OHDA-pretreated rats, baseline values of MBP were significantly decreased compared to those in vehicle-pretreated control rats (96.3±4.2 vs 108.0±1.9 mmHg, P<0.05). PGE2 at 1 nmol significantly increased MBP and the increment was abolished by 6-OHDA (Fig. 2A). On the other hand, 6-OHDA showed no significant effect on the PGE2-induced increments in ICI or TP (Fig. 2B-2C). Icv pretreated SC51322 and PF04418948, but not L-798106 or L-161982, significantly attenuated the PGE2-induced increments in ICI and TP (Fig. 3). Icv administered PGE2 increased ICI and TP, and TP can be increased by urethral contraction. Since icv administered PGE2 was reported to elevate plasma noradrenaline [2], the PGE2-induced ICI increments might be mediated at least by increased urethral resistance induced by noradrenaline. In 6-OHDA-pretreated rats, chemical sympathectomy was induced evidenced by decreased basal MBP. Icv administered PGE2 increased MBP and the increment was abolished by 6-OHDA, which showed no effect on the PGE2-induced increments in ICI or TP. Therefore, it is assumed that centrally administered PGE2 suppressed the rat micturition reflex independently of the sympathetic nervous system (SNS) activation. Our results of experiments using EP receptor antagonists suggest that brain EP1 and EP2, but not EP3 or EP4, receptors are involved in the PGE2-induced suppression of the micturition reflex. Previously, it is reported that in rats, icv administered PGE2 increased bladder capacity (BC), while local administration of PGE2 into the periaqueductal gray (PAG) decreased BC through EP1 receptors [3]. In addition, PGE2 administered into the PAG decreased BC at 28 pmol, but not 280 pmol, in rats [3]. These data suggest that roles of brain PGE2 in regulation of the micturition reflex might be vary depending on action sites and local contents of brain PGE2. Further studies are needed to clarify brain specific regions that contribute to brain PGE2 and EP1/EP2 receptors-mediated suppression of the micturition reflex. Centrally administered PGE2 suppresses the rat micturition reflex via brain EP1 and EP2 receptors independently of the SNS activation. Therefore, brain PGE2 and EP1/EP2 receptors could be novel therapeutic targets for patients with LUT dysfunctions attributed to neurogenic bladder overactivity. [Display omitted] [Display omitted] Funding JSPS KAKENHI Grant (#23K06887), Grant from The Smoking Research Foundation in Japan and The Kochi Medical School Hospital President’s Discretionary Grant. Clinical Trial No Subjects Animal Species Rat Ethics Committee The Kochi University Institutional Animal Care and Use Committee
AbstractList Hypothesis / aims of studyProstaglandin E2 (PGE2) is reported to facilitate the micturition reflex at levels of the lower urinary tract (LUT) and the spinal cord [1]. However, roles of brain PGE2 in regulation of the reflex are unclear. In previous reports, intracerebroventricularly (icv) administered PGE2 elevated plasma noradrenaline [2], which can affect the micturition reflex. In this study, therefore, we investigated effects of icv administered PGE2 on the rat micturition reflex. Study design, materials and methodsIn urethane-anesthetized (0.8 g/kg, ip) male Wistar rats (300-450 g), a catheter was inserted into the bladder to perform cystometry. Two hours after the surgery, cystometry (saline instillation at 12 ml/h) was started to evaluate intercontraction interval (ICI), threshold pressure for inducing micturition (TP) and maximal voiding pressure (MVP). One hour after the start, PGE2 (0.1, 0.3 or 1 nmol/rat) or vehicle was icv administered. Evaluations of these parameters were continued 2 h after the administration. When using each antagonist for E-prostanoid receptor subtypes (EP1-EP4), SC51322 (EP1 antagonist), PF04418948 (EP2 antagonist), L-798106 (EP3 antagonist) or L-161982 (EP4 antagonist) was icv pretreated at 100 nmol/rat 30 min before PGE2 administration (1 nmol/rat, icv). In some rats, 6-hydroxydopamine (6-OHDA), which induces chemical sympathectomy, was administered (100 mg/kg, ip) once a day for 3 days. At one day after the third administration, PGE2 was administered (1 nmol/rat, icv) and urodynamic parameters were evaluated in addition to measuring mean blood pressure (MBP) through an arterial catheter. ResultsPGE2 dose-dependently increased ICI and TP (Fig. 1) without changing MVP (data not shown). In 6-OHDA-pretreated rats, baseline values of MBP were significantly decreased compared to those in vehicle-pretreated control rats (96.3±4.2 vs 108.0±1.9 mmHg, P<0.05). PGE2 at 1 nmol significantly increased MBP and the increment was abolished by 6-OHDA (Fig. 2A). On the other hand, 6-OHDA showed no significant effect on the PGE2-induced increments in ICI or TP (Fig. 2B-2C). Icv pretreated SC51322 and PF04418948, but not L-798106 or L-161982, significantly attenuated the PGE2-induced increments in ICI and TP (Fig. 3). Interpretation of resultsIcv administered PGE2 increased ICI and TP, and TP can be increased by urethral contraction. Since icv administered PGE2 was reported to elevate plasma noradrenaline [2], the PGE2-induced ICI increments might be mediated at least by increased urethral resistance induced by noradrenaline. In 6-OHDA-pretreated rats, chemical sympathectomy was induced evidenced by decreased basal MBP. Icv administered PGE2 increased MBP and the increment was abolished by 6-OHDA, which showed no effect on the PGE2-induced increments in ICI or TP. Therefore, it is assumed that centrally administered PGE2 suppressed the rat micturition reflex independently of the sympathetic nervous system (SNS) activation. Our results of experiments using EP receptor antagonists suggest that brain EP1 and EP2, but not EP3 or EP4, receptors are involved in the PGE2-induced suppression of the micturition reflex. Previously, it is reported that in rats, icv administered PGE2 increased bladder capacity (BC), while local administration of PGE2 into the periaqueductal gray (PAG) decreased BC through EP1 receptors [3]. In addition, PGE2 administered into the PAG decreased BC at 28 pmol, but not 280 pmol, in rats [3]. These data suggest that roles of brain PGE2 in regulation of the micturition reflex might be vary depending on action sites and local contents of brain PGE2. Further studies are needed to clarify brain specific regions that contribute to brain PGE2 and EP1/EP2 receptors-mediated suppression of the micturition reflex. Concluding messageCentrally administered PGE2 suppresses the rat micturition reflex via brain EP1 and EP2 receptors independently of the SNS activation. Therefore, brain PGE2 and EP1/EP2 receptors could be novel therapeutic targets for patients with LUT dysfunctions attributed to neurogenic bladder overactivity. Figure 1Fig. 1 and 2 Figure 2Fig. 3 Funding JSPS KAKENHI Grant (#23K06887), Grant from The Smoking Research Foundation in Japan and The Kochi Medical School Hospital President’s Discretionary Grant. Clinical Trial No Subjects Animal Species Rat Ethics Committee The Kochi University Institutional Animal Care and Use Committee
Prostaglandin E2 (PGE2) is reported to facilitate the micturition reflex at levels of the lower urinary tract (LUT) and the spinal cord [1]. However, roles of brain PGE2 in regulation of the reflex are unclear. In previous reports, intracerebroventricularly (icv) administered PGE2 elevated plasma noradrenaline [2], which can affect the micturition reflex. In this study, therefore, we investigated effects of icv administered PGE2 on the rat micturition reflex. In urethane-anesthetized (0.8 g/kg, ip) male Wistar rats (300-450 g), a catheter was inserted into the bladder to perform cystometry. Two hours after the surgery, cystometry (saline instillation at 12 ml/h) was started to evaluate intercontraction interval (ICI), threshold pressure for inducing micturition (TP) and maximal voiding pressure (MVP). One hour after the start, PGE2 (0.1, 0.3 or 1 nmol/rat) or vehicle was icv administered. Evaluations of these parameters were continued 2 h after the administration. When using each antagonist for E-prostanoid receptor subtypes (EP1-EP4), SC51322 (EP1 antagonist), PF04418948 (EP2 antagonist), L-798106 (EP3 antagonist) or L-161982 (EP4 antagonist) was icv pretreated at 100 nmol/rat 30 min before PGE2 administration (1 nmol/rat, icv). In some rats, 6-hydroxydopamine (6-OHDA), which induces chemical sympathectomy, was administered (100 mg/kg, ip) once a day for 3 days. At one day after the third administration, PGE2 was administered (1 nmol/rat, icv) and urodynamic parameters were evaluated in addition to measuring mean blood pressure (MBP) through an arterial catheter. PGE2 dose-dependently increased ICI and TP (Fig. 1) without changing MVP (data not shown). In 6-OHDA-pretreated rats, baseline values of MBP were significantly decreased compared to those in vehicle-pretreated control rats (96.3±4.2 vs 108.0±1.9 mmHg, P<0.05). PGE2 at 1 nmol significantly increased MBP and the increment was abolished by 6-OHDA (Fig. 2A). On the other hand, 6-OHDA showed no significant effect on the PGE2-induced increments in ICI or TP (Fig. 2B-2C). Icv pretreated SC51322 and PF04418948, but not L-798106 or L-161982, significantly attenuated the PGE2-induced increments in ICI and TP (Fig. 3). Icv administered PGE2 increased ICI and TP, and TP can be increased by urethral contraction. Since icv administered PGE2 was reported to elevate plasma noradrenaline [2], the PGE2-induced ICI increments might be mediated at least by increased urethral resistance induced by noradrenaline. In 6-OHDA-pretreated rats, chemical sympathectomy was induced evidenced by decreased basal MBP. Icv administered PGE2 increased MBP and the increment was abolished by 6-OHDA, which showed no effect on the PGE2-induced increments in ICI or TP. Therefore, it is assumed that centrally administered PGE2 suppressed the rat micturition reflex independently of the sympathetic nervous system (SNS) activation. Our results of experiments using EP receptor antagonists suggest that brain EP1 and EP2, but not EP3 or EP4, receptors are involved in the PGE2-induced suppression of the micturition reflex. Previously, it is reported that in rats, icv administered PGE2 increased bladder capacity (BC), while local administration of PGE2 into the periaqueductal gray (PAG) decreased BC through EP1 receptors [3]. In addition, PGE2 administered into the PAG decreased BC at 28 pmol, but not 280 pmol, in rats [3]. These data suggest that roles of brain PGE2 in regulation of the micturition reflex might be vary depending on action sites and local contents of brain PGE2. Further studies are needed to clarify brain specific regions that contribute to brain PGE2 and EP1/EP2 receptors-mediated suppression of the micturition reflex. Centrally administered PGE2 suppresses the rat micturition reflex via brain EP1 and EP2 receptors independently of the SNS activation. Therefore, brain PGE2 and EP1/EP2 receptors could be novel therapeutic targets for patients with LUT dysfunctions attributed to neurogenic bladder overactivity. [Display omitted] [Display omitted] Funding JSPS KAKENHI Grant (#23K06887), Grant from The Smoking Research Foundation in Japan and The Kochi Medical School Hospital President’s Discretionary Grant. Clinical Trial No Subjects Animal Species Rat Ethics Committee The Kochi University Institutional Animal Care and Use Committee
ArticleNumber 102260
Author Tsubouchi, S
Higashi, Y
Saito, M
Shimizu, T
Togo, M
Shimizu, N
Author_xml – sequence: 1
  givenname: T
  surname: Shimizu
  fullname: Shimizu, T
  organization: Department of Pharmacology, Kochi Medical School, Kochi University
– sequence: 2
  givenname: N
  surname: Shimizu
  fullname: Shimizu, N
  organization: Pelvic Floor Center, Kochi Medical School, Kochi University
– sequence: 3
  givenname: S
  surname: Tsubouchi
  fullname: Tsubouchi, S
  organization: Department of Pharmacology, Kochi Medical School, Kochi University
– sequence: 4
  givenname: M
  surname: Togo
  fullname: Togo, M
  organization: Department of Pharmacology, Kochi Medical School, Kochi University
– sequence: 5
  givenname: Y
  surname: Higashi
  fullname: Higashi, Y
  organization: Department of Pharmacology, Kochi Medical School, Kochi University
– sequence: 6
  givenname: M
  surname: Saito
  fullname: Saito, M
  organization: Department of Pharmacology, Kochi Medical School, Kochi University
BookMark eNqFkd1KAzEQhYNUsFZfwKu8wNZkdje7FRGk1B8QFPTCu5BNppq6zS5JKvbtzVIvRFCvJszwnZw5c0hGrnNIyAlnU864OF1NdefiFBiUqQEg2B4ZQ1VBNqvyavTtfUCOQ1gxxqDmPC_KMQl5LmhG5-iiV227pcqsrbMhokdDe9-FqF5a5Yx1dAE0bPreYwgYaHxF6lWka6vjxttoO0c9Llv8oO9W0carAXngNMGpQhpq7GPnwxHZX6o24PFXnZCnq8XT_Ca7u7--nV_eZRoKwbJcCSgF1FjoptE1N9woBIZQpJ5ZlsiMqHmjcy5UiYCFEbNGQ7VE06hmlk8I7GR12iIka7L3dq38VnImh-DkSg7BySE4uQsuQec7CJOxd4teBm3RaTQ2-Y_SdPZv_OIHrtsUp1btG24xrLqNd2llyWUAyeTjcJnhMFAyVlfVcxI4-13gv98_AYIeogw
Cites_doi 10.1016/j.ejphar.2009.03.057
10.1016/j.bcp.2020.114363
ContentType Journal Article
Copyright 2025 © 2025 The Authors. Published by Elsevier B.V. on behalf of International Continence Society
2025 The Authors. Published by Elsevier B.V. on behalf of International Continence Society
Copyright_xml – notice: 2025 © 2025 The Authors. Published by Elsevier B.V. on behalf of International Continence Society
– notice: 2025 The Authors. Published by Elsevier B.V. on behalf of International Continence Society
DBID 6I.
AAFTH
AAYXX
CITATION
DOI 10.1016/j.cont.2025.102260
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
CrossRef
DatabaseTitle CrossRef
DatabaseTitleList


DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2772-9737
EndPage 102260
ExternalDocumentID 10_1016_j_cont_2025_102260
S277297372500877X
1_s2_0_S277297372500877X
GroupedDBID .1-
.FO
0R~
AALRI
AAXUO
AAYWO
ACVFH
ADCNI
ADVLN
AEUPX
AEXQZ
AFJKZ
AFPUW
AFRHN
AIGII
AITUG
AJUYK
AKBMS
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
APXCP
EBS
FDB
GROUPED_DOAJ
M41
M~E
ROL
Z5R
6I.
AAFTH
AAYXX
CITATION
ID FETCH-LOGICAL-c2460-3a625628e4cbbc81d1dae20e2428edf5e0d681bc316a5e2e4d69bc27fedbab93
ISSN 2772-9737
IngestDate Thu Sep 18 00:24:14 EDT 2025
Sat Sep 27 17:13:57 EDT 2025
Sat Sep 27 20:32:06 EDT 2025
Sat Sep 27 06:10:41 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Language English
License http://creativecommons.org/licenses/by-nc-nd/4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c2460-3a625628e4cbbc81d1dae20e2428edf5e0d681bc316a5e2e4d69bc27fedbab93
OpenAccessLink http://dx.doi.org/10.1016/j.cont.2025.102260
PageCount 1
ParticipantIDs crossref_primary_10_1016_j_cont_2025_102260
elsevier_sciencedirect_doi_10_1016_j_cont_2025_102260
elsevier_clinicalkeyesjournals_1_s2_0_S277297372500877X
elsevier_clinicalkey_doi_10_1016_j_cont_2025_102260
PublicationCentury 2000
PublicationDate 2025
2025-00-00
PublicationDateYYYYMMDD 2025-01-01
PublicationDate_xml – year: 2025
  text: 2025
PublicationDecade 2020
PublicationTitle Continence (Amsterdam)
PublicationYear 2025
Publisher Elsevier B.V
Publisher_xml – name: Elsevier B.V
References Nakai, Yusup, Taisei (bib3) 2026; 25
Hou, Yu, Jiang (bib1) 2021; 184
Shimizu, Yokotani (bib2) 2009; 611
Hou (10.1016/j.cont.2025.102260_bib1) 2021; 184
Nakai (10.1016/j.cont.2025.102260_bib3) 2026; 25
Shimizu (10.1016/j.cont.2025.102260_bib2) 2009; 611
References_xml – volume: 611
  start-page: 30
  year: 2009
  end-page: 34
  ident: bib2
  article-title: Effects of centrally administered prostaglandin E3 and thromboxane A3 on plasma noradrenaline and adrenaline in rats: comparison with prostaglandin E2 and thromboxane A2
  publication-title: Eur J Pharmacol
– volume: 25
  start-page: 649
  year: 2026
  end-page: 650
  ident: bib3
  article-title: The role of prostaglandin E2 (PGE2) in cerebral infarction associated with detrusor overactivity. An experimental study on the occurrence of neuroplasticity
  publication-title: Neurourol Urodyn
– volume: 184
  start-page: 114363
  year: 2021
  ident: bib1
  article-title: PGE2 receptors in detrusor muscle: Drugging the undruggable for urgency
  publication-title: Biochem Pharmacol
– volume: 611
  start-page: 30
  year: 2009
  ident: 10.1016/j.cont.2025.102260_bib2
  article-title: Effects of centrally administered prostaglandin E3 and thromboxane A3 on plasma noradrenaline and adrenaline in rats: comparison with prostaglandin E2 and thromboxane A2
  publication-title: Eur J Pharmacol
  doi: 10.1016/j.ejphar.2009.03.057
– volume: 25
  start-page: 649
  year: 2026
  ident: 10.1016/j.cont.2025.102260_bib3
  article-title: The role of prostaglandin E2 (PGE2) in cerebral infarction associated with detrusor overactivity. An experimental study on the occurrence of neuroplasticity
  publication-title: Neurourol Urodyn
– volume: 184
  start-page: 114363
  year: 2021
  ident: 10.1016/j.cont.2025.102260_bib1
  article-title: PGE2 receptors in detrusor muscle: Drugging the undruggable for urgency
  publication-title: Biochem Pharmacol
  doi: 10.1016/j.bcp.2020.114363
SSID ssj0002811345
Score 2.2820039
Snippet Prostaglandin E2 (PGE2) is reported to facilitate the micturition reflex at levels of the lower urinary tract (LUT) and the spinal cord [1]. However, roles of...
Hypothesis / aims of studyProstaglandin E2 (PGE2) is reported to facilitate the micturition reflex at levels of the lower urinary tract (LUT) and the spinal...
SourceID crossref
elsevier
SourceType Index Database
Publisher
StartPage 102260
SubjectTerms Urology
Title 336 - Centrally administered prostaglandin E2 suppresses the rat micturition reflex via brain EP1 and EP2 receptors
URI https://www.clinicalkey.com/#!/content/1-s2.0-S277297372500877X
https://www.clinicalkey.es/playcontent/1-s2.0-S277297372500877X
https://dx.doi.org/10.1016/j.cont.2025.102260
Volume 15
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2772-9737
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0002811345
  issn: 2772-9737
  databaseCode: DOA
  dateStart: 20220101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2772-9737
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0002811345
  issn: 2772-9737
  databaseCode: M~E
  dateStart: 20220101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb5wwELa2qVT1EvWpbh-RD70hENg8j1FEFbVKFSlU2puFjWmJsksUlirNof-l_7QzGFi22b5yYVdejI397Xhm_HmGkLe-1mHEZGLHiatsP-DaTnjsg82Ty6DwYuV14ZpOPobHn_z3i2Axm_2YsJbatXTUzc5zJXeZVSiDecVTsv8xs-NDoQC-w_zCFWYYrv80x5yHlj04aC--WXkfCRfzbyLzCjS_LkVHtbJSZjXtZcd6xaAOyCvM19aywh2EjrVlwVJ5oa-tr1VuScwbYaWnXre1kJ4y-BHpL3W_9TNENqgxzUQnGkBPPVxiwwUCbHQunH2pltVNu0XGnpSN20BZ08oa07JsOWOz-nO9cdj2rglzgNnILgZKu51EJp6Lo3eUDcI3mEhPtD5NdoF-Ld4U3JL0xulw7iCj38HGnWntaVjt9OiDZzfMce0z7AL2APQ-DIS42L7ZGEWiYcIVt269R-6zCJQZZId-37jxWOx5vEuFPb5efzTLsAh_7d5u9Wei0mSPyH5vi9BDA6zHZKZXT8iDk55t8ZQ0gC9q0xFfdIovuoUvmjK6wRcFfFHAF53gixp8UcAX7fBFAV8UKsMnoyO-npHsXZodHdt9kg5bMT-ENTwHCzpksfaVlAqsH6_INXM1qH6xLspAu0UIppHiXpgHmmm_CBOpWFTqQuYy4c_J3qpe6ReERr5UZcm5Llzl-2WYy7IEa73UquQ5iJo5sYahE5cmFIsYOIrnAgda4EALM9BzwofRFcMhY1gWBeDnj7WiXbV00__rG_E7fMxJMNbslVejlP6lxZd3bvEVeYjPMf7A12RvfdXqN6Ahr-VB51k66JD6ExgJuWE
linkProvider ISSN International Centre
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=336+-+Centrally+administered+prostaglandin+E2+suppresses+the+rat+micturition+reflex+via+brain+EP1+and+EP2+receptors&rft.jtitle=Continence+%28Amsterdam%29&rft.au=Shimizu%2C+T&rft.au=Shimizu%2C+N&rft.au=Tsubouchi%2C+S&rft.au=Togo%2C+M&rft.date=2025&rft.issn=2772-9737&rft.eissn=2772-9737&rft.volume=15&rft.spage=102260&rft.epage=102260&rft_id=info:doi/10.1016%2Fj.cont.2025.102260&rft.externalDBID=ECK1-s2.0-S277297372500877X&rft.externalDocID=1_s2_0_S277297372500877X
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F27729737%2FS2772973725X00060%2Fcov150h.gif